CURRICULUM VITAE

PETER CHRISTIAN ALBERTSEN University of Connecticut Health Center Division of Urology Farmington, Connecticut 06030-3955 P: 860-679-3676 F: 860-679-1318 E: [email protected]

Education: Princeton University, B.A., Biochemistry, cum laude 1974 Columbia University, M.D. 1978 University of Wisconsin, M.S., Medical Administration and Preventive Medicine 1990

Residency: Fifth (Harvard) Surgical Service 1978-1980 New Deaconess Hospital Boston, MA Brady Urological Institute 1980-1984 Johns Hopkins Hospital Baltimore, MD

Employment: Instructor Brady Urological Institute 1985-1986 Private Practice Baltimore, MD University of Connecticut Health Center Farmington, CT Assistant Professor 1987-1994 Associate Professor 1994-2000 Professor 2000-present Division Chief and Residency Program Director 1995-present Associate Dean for Clinical Research Planning & Administration 2006-present

Awards: Sigma Xi, Princeton Chapter 1974 P & S Alumni Association Bronze Medal 1978 American Urological Association, First Prize Essay 1983 American Society of Andrology, First Prize Essay 1984 Board of Directors Faculty Recognition Award 2005 America’s Top Doctors 2009, 2010, 2011

Licensed: Connecticut 1987 Certified: American Board of Urology 1986 Recertified 1994, 2004

National & Regional Appointments:

Trustee - American Board of Urology 2001-2007 President - American Association of Clinical Urologists 2005-2006 President - New England Section of the American Urological Association 2004-2005 President - Society of University Urologists 2008-2009 Residency Review Committee - ACGME for Urology 2003-2009 Chairman, Cause of Death Committee - National Cancer Institute PLCO Screening Trial, 1999-present New England Section Representative - American Association Clinical Urologists 1998-2004 Connecticut Representative - New England Section of the American Urological Association 1997-1999 Historian - New England Section American Urological Association 2002-2004 National Blue Cross/Blue Shield Technology Assessment Panel 1997-present

NIH Study Section (Epidemiology and Disease Control – 2) 1996-1998 Committee on Third Party Payers - Hartford County Medical Association 1989-1995 Board Member - Hartford County Medical Society 1994-2000 President - Hartford County Medical Association 1998-1999 Vice President - Hartford County Medical Association 1997-1998 Secretary/Treasurer - Hartford County Medical Association 1996-1997 Socio-economic Consultant - BPH guidelines panel of the Agency for Healthcare Research & Quality 1990-1993 Socio-economic Representative (New England Section) - American Urological Association 1989-2002 Board Chairman - Health Management Corporation, a subsidiary of ConnectiCare, Inc. 1994-1999 Board Member - Health Management Corporation, a subsidiary of ConnectiCare, Inc. 1991-1994 Board Member - Drug Utilization Review, State of Connecticut Department of Income Maintenance 1991-1995

Editorial Boards:

Urology 1993-present Urology Times 1993-present Journal of Urology – Urological Survey 2000-2006 Urologic Oncology 2001-2006

Reviewer:

Cancer 1995-present Investigative Urology 2000-present JAMA 1994-present Journal of the National Cancer Institute 1994-present Journal of Urology 1994-present New England Journal of Medicine 1997-present Urology 1994-present

Institutional Appointments:

Medical Director, Operating Room, John Dempsey Hospital 1990-1991 Chairman, Operating Room Committee 1990-1991 Associate Dean, Continuing Medical Education 1991-1994 Chairman, Ambulatory Operations Committee, University Physicians 1991-1993 Chairman, Managed Health Care Committee, University Physicians 1992-1993 Interim Medical Director, University Physicians 1993-1996 Clinical Governance Committee 1997-2006 Chairman, Finance Funds and Flow Committee 1999-2001 Chairman, Strategic Planning Committee 2002-2006 Compensation Committee 2003-2006 Senior Appointments and Promotions Committee 2004-2006 Associate Dean for Clinical Affairs 2006-2010 Chairman, Clinical Council Finance Subcommittee 2006-present

Research Projects: Total Award

Evaluation of Atamestane of Benign Prostatic Hyperplasia 6/1/91-12/31/94 $20,726 Berlex Laboratories Prostate Cancer : A Retrospective Survival Analysis Year 01 8/1/91-7/30/92 $224,376 U.S. Public Health Service A Double Blind Study to Investigate Long-Term Effects of Finasteride 11/20/91-2/28/99 $129,759 Covance/Merck Research Laboratories A 16-Week Double-Blind Placebo-Controlled Dose-Titration Study Using Doxazosin Tablets $26,008 for the Treatment of Benign Prostatic Hyperplasia in Normotensive Patients 12/1/91-11/30/95 Pfizer, Inc Prostate Cancer : A Retrospective Survival Analysis Year 02 8/1/92-7/30/93 $166,678 U.S. Public Health Service Port II for Prostatic Diseases Year 01 9/1/94-8/31/95 $155,992 National Institutes of Health Port II for Prostatic Diseases Year 02 9/1/95-1/31/96 $132,604 National Institutes of Health Pilot Study on Measurement of Utilities in Prostate Cancer 11/1/95-10/31/96 $143,478 Dept. of Public Health and Addiction Services Port II for Prostatic Diseases Year 03 2/1/96-10/31/97 $28,255 National Institutes of Health Prostate Cancer Practice Patterns & Quality of Life Phase I 8/1/96-7/31/97 $223,040 Connecticut Department of Public Health Prostate Cancer Practice Patterns & Quality of Life Phase II 8/1/97-5/31/98 $81,703 Connecticut Department of Public Health Trends in Prostate Cancer Mortality 9/30/97-9/29/98 $102,480 Connecticut Department of Public Health Prostate Cancer Practice Patterns & Health Related Quality of Life Phase III 9/30/97-10/31/98 $63,538 Connecticut Department of Public Health Port II for Prostatic Diseases Year 04 11/1/97-10/31/98 $36,110 National Institutes of Health Mechanisms of Chronic Prostatitis Year 01 7/7/97-5/31/98 $229,919 National Institutes of Health Port II for Prostatic Diseases Year 05 10/31/98-8/31/99 $36,745 National Institutes of Health Mechanisms of Chronic Prostatitis Year 02 6/1/98-5/31/99 $236,887 National Institutes of Health Comparison of Treatment Efficacy for Prostate Cancer 9/1/98-8/31/03 $1,413,757 Agency Health Care Policy and Research Prostate Cancer Practice Patterns & Quality of Life Phase IV 11/1/98-6/29/99 $34,929 Connecticut Department of Public Health Prostate Cancer Practice Patterns & Quality of Life Phase V 7/1/99-/3/31/01 $267,195 Connecticut Department of Public Health Prostate Cancer Practice Patterns & Quality of Life Phase VI 1/1/01-6/30/01 $19,715 Connecticut Department of Public Health A Study to Determine Minimum Difference for Patients with Benign Prostatic Hyperplasia $14,350 10/28/98-10/27/00 Glaxo Welcome Mechanisms of Chronic Prostatitis Year 03 6/1/99-5/31/00 $243,259 National Institutes of Health Intergovernmental Personnel Act – P. Albertsen 12/1/99-3/1/01 $44,099 Centers for Disease Control & Prevention Mechanisms of Chronic Prostatitis Year 04 6/1/00-5/31/01 $249,914 National Institutes of Health

Prostate Cancer Outcomes Study Phase VI 1/1/01-7/31/01 $19,715 Connecticut Department of Public Health Prostate Cancer Outcomes Study Phase VII 7/7/01/-6/30/02 $119,137 Connecticut Department of Public Health Benign Prostatic Hyperplasia Alpha-Adrenergic Antagonist 07/1/01-12/31/03 $24,774 Pharmaceutical Research Assoc. Prostate Cancer Outcomes Study Phase VIII 8/15/02-7/31/03 $17,299 Connecticut Department of Pubic Health The Selenium and Vitamin E Chemoprevention Trial (SELECT) 09/1/01- 5/31/13 $149,430 Southwest Oncology Group Prostate Cancer Screening & Mortality Seattle VS. Connecticut Year 01 9/30/01-9/29/02 $12,365 Massachusetts General Hospital Prostate Cancer Screening & Mortality Seattle VS. Connecticut Year 02 9/30/02-9/29/03 $14,952 Massachusetts General Hospital The Effect of Zometa compared to Placebo on Bone Mineral Density in Patients Undergoing $3,878 Androgen Deprivation Therapy 3/15/03 – 3/15/05 Novartis Pharmaceutical Corporation Prostate Cancer Outcomes Study Phase IX 9/30/03-9/29/04 $16,885 Connecticut Department of Public Health Prostate Cancer Screening & Mortality Seattle VS. Connecticut Year 03 9/30/03-9/29/04 $10,312 Massachusetts General Hospital Prostate Cancer Screening & Mortality Seattle VS. Connecticut Year 04 9/30/04-3/31/06 $ 7,095 Massachusetts General Hospital Development of a Predictive Model for Prostate Cancer Progression 4/18/06-4/17/07 $38,000 Aureon Laboratories, Inc Evaluation of Palliative Prostate Cancer among Elderly Men 8/1/06 – 7/31/11 $43,591 University of Medicine & Dentistry of New Jersey / Robert Wood Johnson Medical School (NCI) Prostate Tissue Array Project 9/15/06-9/14/11 $50,000 The V Foundation for Cancer Research Race, Co-morbidity and Long Term Prostate Cancer Outcomes 8/1/07 – 7/31/10 $164,012 University of Southern California, Los Angeles (NCI) A Randomized, Open Label, Multicenter, Phase III, 2-Arm Study of Androgen Deprivation with $12,400 Leuprolide, +/- Docetaxel for Clinically Asymptomatic Prostate Cancer Subjects with a Rising PSA Following Definitive Local Therapy 7/2/07 – 9/30/11 Sanofi - Aventis Evaluation of Circulating Tumor Cell Measurements in Diagnosis of Prostate Cancer $14,259 3/3/08-2/24/10 Ikonisys

PUBLICATIONS

1. Albertsen PC.* Histologic Grading and the Practicing Urologist. The Prostate 1982; 3:333-338. 2. Albertsen PC,* Marshall F, Optimal Management of Prostate Cancer. Geriatrics 1982; 37:69-79. 3. Albertsen PC*, Chang TSK. Hormone Measurements in the Assessment of Male Infertility. J Clin Immunoassay 1983; 6:51-56. 4. Albertsen PC*, Chang TSK, Vindivich D, Robinson JC, JW. A Critical Method of Evaluating Tests for Male Infertility. J Urol 1983; 130:467-475. 5. Albertsen PC*, Albertsen PS. Evaluation of a New Nonadhesive Urine Collection Device for Patients with Ileal Conduits. J Urol 1984; 131:454-455. 6. Chang TSK, Albertsen PC. Interpretation and Utilization of the Zona Pellucida-Free Hamster Egg Penetration Test in the Evaluation of the Infertile Male. Seminars in Urology 1984; 2:124-130. 7. Brendler CB, Albertsen PC, Goldman SM, Hill GS, Lowe FC, Millan JC. Acquired Renal Cystic Disease in the End- Stage Kidney: Urological Implications. J Urol 1984; 132:548-552. 8. Nadel SN, Hutchins GM, Albertsen PC, White RI. Valves of the Internal Spermatic Vein: Potential for Misdiagnosis of Varicocele by Venography. Fertility & Sterility 1984; 41:479-481. 9. Oesterling JE, Bromberg WD, Albertsen PC*. Xeroradiography and Ultrasonography in the Evaluation of a Penile Injury. J Urol 1986; 135:791-793. 10. Gearhart J, Albertsen PC, Jeffs RD. Applications of Augmentation Cystoplasty: The Johns Hopkins Experience. J Urol 1986; 136:430-435. 11. Albertsen PC*, Kamens EA. Variations in Coding Practices Among Connecticut Urologists for the Medicare Population. Connecticut Medicine 1990; 54:508-512. 12. Small JD, Albertsen PC, Graydon RJ, Ricci A, and Sardell WV. Adenoid Cystic Carcinoma of Cowper's Gland. J Urol 1992; 147:699-701. 13. Fleming C, Wasson J, Albertsen PC, Barry M, and the Prostate PORT. A Decision Analysis of Alternative Treatment for Clinically Localized Prostate Cancer. JAMA 1993; 269:2650-2658. 14. Wasson J, Fleming C, Brusrewitz R, Albertsen PC, Barry M, Yad G, Wennberg J, Littenburg B, Mullty A. The Treatment of Localized Prostate Cancer: What are We Doing, What Do We Know, and What Should We Be Doing? Seminars in Urology 1993; 11:23-26. 15. Cromley EK, Albertsen PC. Patterns of Multiple-Site Physician Practices. Health Services Research 1993; 28:503- 522. PMCID: PMC1069954 16. Albertsen PC*. Computer Modeling and Decision-Making: Clinical Applications in Bladder Cancer. Seminars in Urology 1993; 11:171-176. 17. Albertsen PC*, Fine J. Building Population Data Bases: Lessons From a Community Project. Clinical Performance and Quality Health Care 1993; 1(4):191-193. 18. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The Role of Increasing Detection in the Rising Incidence of Prostate Cancer. JAMA 1995; 273:548-552. 19. Albertsen PC*, Fine J. Prostate biopsy in the Community. Who are the most likely Candidates? Contemporary Urology 1995; 7:54-57. 20. Albertsen PC*. A 72-Year Old Man with Localized Prostate Cancer. JAMA 1995; 274:69-74. 21. Albertsen PC*, Fryback DG, Storer DE, Kolon TF, Fine J. Long-term Survival among Men with Conservatively Treated Localized Prostate Cancer. JAMA 1995; 274:626-631. 22. Mulhall JP, Albertsen PC*. Hemospermia: Diagnosis and Treatment. Urology 1995; 46:463-467. 23. Wasson JH, Albertsen PC. Prostate Disease: An Emergency only for the Patient. Emergency Medicine 1995; 27:20- 40. 24. Gee WF, Holtgrewe L, Albertsen PC, Litwin MS, Manyak MJ, O'Leary MP, Painter MR. Practice Trends in the Diagnosis and Management of Benign Prostatic Hyperplasia in the United States. J Urol 1995; 154:205-206. 25. Gee WF, Holtgrewe L, Albertsen PC, Litwin MS, Manyak MJ, O'Leary MP, Painter MR. Practice Trends in the Diagnosis and Management of Prostate Cancer in the United States. J Urol 1995; 154:207-208. 26. Albertsen PC*, Fryback DG, Storer BE, Kolon TF, Fine J. The Impact of Co-morbidity on Life Expectancy Among Men with Localized Prostate Cancer. J Urol 1996; 156:127-132. 27. Albertsen PC*. African-Americans and Prostate Cancer. Cancer Journal from Scientific American 1996; 2(4):2000. 28. Lu-Yao GL, Potosky AL, Albertsen PC, Wasson JH, Barry MJ, Wennberg JE. Followup Prostate Cancer Treatments After Radical Prostatectomy - a Population Based Study. JNCI 1996; 88:166-173.

29. Welch WG, Albertsen PC, Nease RF, Bubocz TA, Wasson JH. Estimating Treatment Benefits for the Elderly - the Effect of Competing Risks. Ann Int Med 1996; 124:577-584. 30. Albertsen PC*. (Editorial) Defining Clinically Significant Prostate Cancer: Pathologic Criteria vs. Outcomes Data. JNCI 1996; 88:1177-1178. 31. Gee WF, Holtgrewe L, Albertsen PC, Litwin MS, Manyak MJ, O’Leary MP, Painter MR, Blizzard RT, Fenninger RB, Emmons L. Practice Trends of American Urologists in the Treatment of Impotence, Incontinence and Infertility. J Urol 1996; 156:1778-1789. 32. Welch WG, Albertsen PC, Wasson JH. Assessing Competing Risks in Treating the Elderly. Hosp Practice 1996; 31:155-166 33. Albertsen PC*. Contempo 1996: Urology. JAMA 1996; 275: 1857-8. 34. Albertsen PC*. Understanding Managed Care Contracts: a Primer for Urologists. AUA Update Series 1996; 15:190- 195. 35. Albertsen PC*. Screening for Prostate Cancer is neither Appropriate nor Cost-Effective. Urologic Clinics of North America 1996; 23(4):521-530. 36. Albertsen PC*, Aaronson NK, Muller NJ, Keller SD, Ware JE. Health Related Quality of Life among Patients with Metastatic Prostate Cancer. Urology 1997; 49:207-217. 37. Albertsen PC*. Urologic ‘Nuisances’: How to Work up and Relieve Men’s Symptoms. Geriatrics 1997; 52:46-55. 38. Albertsen PC*. Unraveling the Epidemiology of Prostate Cancer. J Urol 1997; 157:2223. 39. Ferrer FA, Miller LJ, Ramez IA, Kurtzman SH, Albertsen PC, Laudone VP, Kreutzer DL. Vascular Endothelial Growth Factor (VEGF) Expression in Human Prostate Cancer: In situ and In vitro Expression of VEGF by Human Prostate Cancer Cells. J Urol 1997; 157:2329-2333 40. Albertsen PC*. Prostate Disease in Older Men: 1. Benign Hyperplasia. Hospital Practice 1997; 32:61-81. 41. Albertsen PC*. The Promise of Outcomes Research. Contemporary Urology 1997; 9(5):27-33. 42. Albertsen PC*. Contempo 1997:Urology. JAMA 1997; 277:1904-1905. 43. Albertsen PC*. Editorial Comment on Temporal Trends In Rates of Prostate Cancer: Declining Incidence of Advanced Disease, 1974-1994. J Urol 1997; 158:1430. 44. Albertsen PC*. Prostate Disease in Older Men: 2. Cancer. Hospital Practice 1997;32:159-181. 45. Onel E, Hammond C, Wasson JH, Berlin BB, Ely MG, Laudone VP, Tarantino AE, Albertsen PC*. An Assessment of the Feasibility and Impact of Shared Decision Making in Prostate Cancer. Urology 1998;51:63-66. 46. Albertsen PC*, Nease RF Jr., Potosky AL. Assessment of Patient Preferences Among Men with Prostate Cancer. J Urol 1998; 159: 158-163. 47. Ferrer FA, Miller LJ, Andrawis, RI, Kurtzman SH, Albertsen PC, Laudone PC, Kreutzer DL. Angiogenesis and Prostate Cancer: In Vivo and In Vitro Expression of Angiogenesis Factors by Prostate Cancer Cells. Urology 1998; 51:161-167. 48. Gee WF, Holtgrewe HL, Albertsen PC, Cooper TP, Fenninger RB, Litwin MS, Manyak MJ, Meyer JJ, Miles BJ, O’Leary MP, Painter MR, Rohner TH, Thomas R, Blizzard RT, Emmons L. Subspecialization, Recruitment and Retirement Trends of American Urologists. J Urol 1998; 159:509-511. 49. Albertsen PC*. Computer Modeling—What should we look for? J Urol 1998; 159:934. 50. Albertsen PC*. Outcomes Research: A Primer for Urologists. AUA Update Series 1998; 14:106-112. 51. McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe LH, Albertsen PC, Roehborn CG, Nickel JC, Wang DZ, Taylor AM, Waldstreicher J. The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment among Men with Benign Prostatic Hyperplasia. N Eng J Med 1998; 338:557-563. 52. Richman AM, Mayne ST, Jekel JF, Albertsen PC. Image Analysis combined with Visual Cytology in the Early Detection of Recurrent Bladder Carcinoma. Cancer 1998; 82:1738-48. 53. Albertsen PC*, Hanley JA, Gleason DF, Barry MJ. A Competing Risk Analysis of Men Age 55-74 Years at Diagnosis Managed Conservatively for Clinically Localized Prostate Cancer. JAMA 1998; 280:975-980. 54. Albertsen PC* Hanley JA, Murphy Setzko M. Statistical Considerations When Assessing Outcomes Following Treatment for Prostate Cancer. J Urol 1999; 162:439-444. 55. Lu-Yao GL, Albertsen PC, Warren J, Yao SL. Effect of Age and Surgical Approach on Complications and Short Term Mortality Following Radical Prostatectomy: A Population Based Study. Urology 1999; 54:301-307. 56. Seidenfeld J, Samson DJ, Aronson N, Albertsen PC, Bayoumi AM, Bennett C, Brown A, Garber A, Gere M, Hasselblad V, Wilt T, Ziegler K. Relative Effectiveness and Cost-Effectiveness of Methods of Androgen Suppression in the Treatment of Advanced Prostate Cancer. Evidence Report: Technology Assessment (Summary) 1999; (4):I-x, 1- 246, Il-36. 57. Albertsen PC*. Who Needs to Be Treated? Molecular Urology 1999; 3(3):183-190.

58. Fowler JF Jr, Collins MM, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Comparison of Recommendations by Urologists and Radiation Oncologists for Treatment of Clinically Localized Prostate Cancer. JAMA 2000; 238:3217- 3222. 59. Albertsen PC, Pellissier JM, Lowe FC, Girman CJ, Roehrborn CG for the PLESS Study Group. Economic Analysis of Finasteride: A Model Based Approach Using Data from the Proscar Long-term Efficacy and Safety Study. Clinical Therapeutics 1999; 21:1006-1024. 60. Ferrer FA, Miller LJ, Lindquist R, P, Laudone VP, Albertsen PC, Kreutzer DL. Expression of Vascular Endothelial Growth Factor Receptors in Human Prostate. Urology 1999; 54:567-572. 61. Gilliland FD, Potosky AL, Harlan LC, Albertsen, PC, Hamilton AS, Eley JW, Stanford JL, Stevenson RA. Predicting Extracapsular Extension of Prostate Cancer in Men Treated by Radical Prostatectomy: Results from the Population- based Prostate Cancer Outcomes Study. J Urol 1999; 162:1341-1345. 62. Potosky AL, Harlan LC. Stanford JL, Gilliland FD, Hamilton AS, Albertsen PC, Eley JW, Liff M, Deapen D, Stephenson RA, Legler J, Gerrans CE, Talcott JA, Litwin MS. Commentary: Assessment of Prostate Cancer Practice Patterns and Quality of Life: The Prostate Cancer Outcomes Study. JNCI 1999; 91:1719-1724. 63. Albertsen PC* Walters S, Hanley JA. A Comparison of Cause of Death Determination Among Men Previously Diagnosed with Prostate Cancer and Dying in Either 1985 or 1995. J Urol 2000; 163:519-523. 64. Sanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL. Urinary and Sexual Function After Radical Prostatectomy for Clinically Localized Prostate Cancer: The Prostate Cancer Outcomes Study. JAMA 2000; 283:354-360. 65. Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, Wilt TJ. Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer: A Systematic Review and Meta-analysis. Ann Int Med 2000; 132:566-577. 66. Albertsen PC*. Editorial Comment. J.Urol. 2000, 163:812. 67. Albertsen PC*. The Significance of Histology in Predicting the Natural History of Prostate Cancer. Prostate J 2000; 2:1-5. 68. McNaughton –Collins M, Fowler FJ Jr., Elliott DB, Albertsen PC, Barry MJ. Diagnosing and Treating Chronic Prostatitis: Do Urologists Use the Four-Glass Test? Urology 2000; 55:403-407. 69. Albertsen PC*, Hanley JA, Harlan LC, Gilliland FD, Hamilton A, Liff JM, Stanford JL, Stephenson RA. Positive Yield of Imaging Studies in the Evaluation of Men with Newly Diagnosed Prostate Cancer: A Population-based Analysis. J Urol 2000; 163:1138-1143. 70. Albertsen PC*. When is Death from Prostate Cancer Not a Death from Prostate Cancer? JNCI 2000; 92(8):590. 71. Fowler FJ, McNaughton-Collins M, Albertsen PC, Zeitman A, Elliott DB, Barry MJ. Comparison of Recommendations by Urologists and Radiation Oncologists for Treatment of Clinically Localized Prostate Cancer. JAMA 2000; 283:3217-3222. 72. Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, Eley JW, Stephenson RA, Harlan LC. Health Outcomes After Radical Prostatectomy or Radiotherapy for Clinically Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study (PCOS). JNCI 2000; 92(1)582-1592. 73. Gomella LG, Albertsen PC, Benson MC, Forman JD, Soloway MS. The Use of Video-based Patient Education for Shared Decision-making in the Treatment of Prostate Cancer. Seminars in Urologic Oncology 2000; 18(3): 182-187. 74. Albertsen PC*. The Natural History of Prostate Cancer. Primary Care & Cancer 2000; 20:8;18-25. 75. D’Alessandri RM, Albertsen PC, Atkinson BF, Dickler RM, Jones RF, Kirch DG, Longnecker DE, McAnarny ER, Parisi VM, Selby SE, Stapczynski S, Thompson JA, Wasserman AG, Zuza KL. Measuring Contributions to the Clinical Mission of Medical Schools and Teaching Hospitals. Academic Medicine 2000; 75:1231-1237. 76. Sneeuw KCA, Albertsen PC, Aaronson NK. Comparison of Patient and Spouse Assessments of Health Related Quality of Life in Men with Metastatic Prostate Cancer. J Urol 2001; 165, 478-482. 77. Albertsen PC*. Comparison of Recommendations by Urologist and Radiation Oncologists for Treatment of Clinically Localized Prostate Cancer. J Urol 2001; 165(2): 731-731. 78. Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL, Albertsen PC, Hamilton AS, Hunt WC, Potosky AL. Racial and Ethnic Differences in Advanced-Stage Prostate Cancer: the Prostate Cancer Outcomes Study. JNCI 2001; 93(5):388-95 79. Barry MJ, Albertsen PC, Bagshaw MA, Blute ML, Cox R, Middleton RG, Gleason DF, Zincke H, Bergstralh EJ, Jacobson SJ. Outcomes for Men with Clinically Nonmetastatic Prostate Carcinoma Managed with Radical Prostactectomy, External Beam Radiotherapy, or Expectant Management: A Retrospective Analysis. Cancer 2001; 91(12): 2302-14.

80. Hamilton AS, Stanford JL, Gilliland FD, Albertsen PC, Stephenson RA, Hoffman RM, Eley JAW, Potosky AL. Health Outcomes after External-Beam Radiation Therapy for Clinically Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study. J Clinical Oncology, 2001; 19(9): 2517-2526. 81. Potosky AL, Knopf K, Clegg LX, Albertsen PC, Stanford JL, Hamilton AS, Gilliland FD, Eley JW, Stephenson RA, Hoffman RM. Quality of Life Outcomes Following Primary Androgen Deprivation Therapy: Results from the Prostate Cancer Outcomes Study. J Clinical Oncology 2001; 19(17): 3750-3757. 82. Penson DF, Albertsen PC, Nelson PS, Barry M, Stanford JL. Determining Cause of Death in Prostate Cancer: Are Death Certificates Valid? JNCI 2001; 93(23): 1822-1823 83. Harlan LC, Potosky AL, Gilliland FD, Hoffman R, Albertsen PC, Hamilton AS, Eley JW, Stanford JL, Stephenson RA. Factors Associated with Initial Therapy for Clinically Localized Prostate Cancer: Results from the Prostate Cancer Outcomes Study. JNCI 2001; 93(24): 1864-1871. 84. Samson D, Seidenfeld J, Wilt T, B, Albertsen PC. Systematic Review and Meta-Analysis of Monotherapy Compared with Combined Androgen Blockage for Advanced Prostate Cancer. Cancer 2002; 95(2): 361-376. 85. Albertsen PC*. Which Results Justify the Means in Prostate Cancer Treatment? Cancer Journal 2002; 8(1):30-32. 86. Miller LJ, Fischer KA, Goralnick SJ, Litt M, Burleson JA, Albertsen PC, Kreutzer DL. Interleukin-10 Levels in Seminal Plasma: Implications for Chronic Prostatitis-Chronic Pain Syndrome. J Urol 2002; 167(2): 753-756. 87. Collins S, Upshaw J, Rutchik S, Ohannessian C, Ortenberg J, Albertsen PC. Effects of Circumcision on Male Sexual Function: Debunking a Myth? J Urol 2002; 167(5): 2111-2112. 88. Schwartz E, Albertsen P. Nomograms for clinically localized disease. Part III: Watchful Waiting. Seminars in Urologic Oncology 2002; 20:140-145. 89. Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, Albertsen PC, Gilliland FD, Stanford JL. Quality of Life Following Localized Prostate Cancer Treated Initially with Androgen Deprivation Therapy or No Therapy. JNCI 2002; 94(6): 430-7. 90. Miller LJ, Fischer KA, Goralnick SJ, Litt M, Burleson JA, Albertsen P, Kreutzer DL. Nerve Growth Factor and Chronic Prostatitis/Chronic Pelvic Pain Syndrome. Urology 2002. 59(4):603-8 91. Taxel P, Fall PM, Albertsen PC, Dowsett RD, Trahiotis M, Zimmerman J, Ohannessian C, Raisz LG. The Effect of Micronized Estradiol on Bone Turnover and Calciotrophic Hormones in Older Men Receiving Hormonal Suppression Therapy for Prostate Cancer. J Clinical Endocrinology and Metabolism 2002; 87(11): 4907-13 92. Penson DF, Albertsen PC. Lessons Learnt About Early Prostate Cancer From Large Scale Databases: Population- based Pearls of Wisdom. Surgical Oncology 2002; 11:3-11. 93. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural Experiment Examining Impact of Aggressive Screening and Treatment on Prostate Cancer Mortality in Two fixed Cohorts from Seattle area and Connecticut. BMJ 2002; 325(7367): 740. PMCID: PMC128373 94. McNaughton-Collins M, Barry MJ, Zietman A, Albertsen PC, Talcott JA, Walker-Corkery E, Elliott DB, Fowler, FJ. United States Radiation Oncologists’ and Urologist’ Opinions about Screening and Treatment of Prostate Cancer vary by Region. Urology 2002; 60(4): 628-33. 95. Albertsen PC*. The conundrum of prostate cancer. The Ca J 2002; 8:432-434. 96. Kessler B, Albertsen PC. The natural history of prostate cancer. Urol Clinics N Am 30 (2003) 219-226. 97. Chakraborty NG, Stevens RL, Mehrotra S, Laska E, Taxel P, Sporn JR, Schauer P, Albertsen PC. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunology, Immunotherapy 2003; 52:497-505. 98. Zeliadt SB, Penson DF, Albertsen PC, Concato J, Etzioni RD. Race independently predicts prostate specific antigen testing frequency following a prostate carcinoma diagnosis. Cancer 2003; 98:496-503 99. Albertsen PC*. The prostate cancer conundrum. JNCI 2003: 95:930-931. 100. Hsieh K, Taylor JA, Albertsen PC. Lower Urinary Tract Symptoms in the Older Male. Connecticut Medicine 2003: 67(8): 487-90. 101. Penson DF, Feng Z, Kuniyaki A, McClerran D, Albertsen PC, Deapen D, Gilliland F, Hoffman R, Stephenson RA, Potosky AL, Stanford JL. General Quality of Life two years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study. J Clin Oncology 2003: 21:1147-1154. 102. Hsieh K, Albertsen PC. Populations at high risk for prostate cancer. Urol Clinics N Am 2003; 30:699-676. 103. Albertsen PC*, Hanley JA, Penson DF, Fine J. Validation of Increasing Prostate Specific Antigen as a Predictor of Prostate Cancer Death After Treatment of Localized Prostate Cancer with Surgery or Radiation. J Urol 2004:171:2221- 2225. 104. Taylor JA 3rd, Kao TC, Albertsen PC, Shabsigh R. Bicycle Riding and its Relationship to the Development of Erectile Dysfunction. J Urol 2004; 172(3):1028-31.

105. Johnson, TK, Gilliland FD, Hoffman RM, Deapen D, Penson DF, Stanford JL, Albertsen PC, Hamilton AS. Racial/Ethnic Differences in Functional Outcomes in the 5 Years After Diagnosis of Localized Prostate Cancer.J Clin Oncology 2004; 22(20):4193-4201 106. Albertsen P*. Editorial Comment on Does the Effectiveness of Bicalutamide in Reducing the Risk of Prostate Cancer Progression Vary with Lymph Node Status? Nature Clinical Practice Urology 2004; 1(1): 3 107. Albertsen PC*. Is Screening for Prostate Cancer with Prostate Specific Antigen an Appropriate Public Health Measure? Acta Oncologica 2005. 44(3):255-264. 108. Albertsen PC*. Prostate-Specific Antigen: How to Advise Patients as the Screening Debate Continues. Cleveland Clinic Journal of Medicine 2005; 72 (6):521-527. 109. Albertsen PC*, Hanley JA, Fine J. Twenty Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer. JAMA 2005; 293: 2095-2101. 110. Penson DF, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, Hamilton A, Hoffman RM, Stephenson RA, Potosky AL, Stanford JL. 5-Year Urinary and Sexual Outcomes after Radical Prostatectomy: Results from the Prostate Cancer Outcomes Study. J Urol 2005; 173(5): 1701-5. 111. Albertsen PC*, Hanley JA, Barrows GH, Penson DF, Kowalczyk PDH, Sanders MM, Fine J. Prostate Cancer and the Will Rogers Phenomenon. JNCI 2005; 97(17):1248-1253. 112. Albertsen PC*. What is the Value of Screening for Prostate Cancer in the US? Nature Clinical Practice Oncology 2005;2(11):2-3. 113. Albertsen PC*. PSA Testing: Public Policy or Private Penchant?. JAMA. 2006;296(19):2371-2373. 114. Albertsen PC*. PSA and the Conservative Treatment of Early Prostate Cancer. Arch Ital Urol Androl 2006 Dec;78(4):152-3. 115. Albertsen PC*, Hanley JA, Penson DF, Barrows G, Fine J. Thirteen Year Outcomes following Treatment for Clinically Localized Prostate Cancer in a Population-based Cohort. J Urol 2007;177:932-936. 116. Albertsen PC*. Commentary: Occult Prostate Cancer -- Imposter or the Real Deal? Intl Jrl of Epidemiology 2007 36:281-282. 117. Albertsen PC*. Commentary on: Does radical prostatectomy provide a survival benefit as primary treatment for high- grade prostate cancer? Nature Clinical Practice Urology 2007; 4(2): 68-69 (2007). 118. Albertsen PC*. What do we really know about prostate cancer?. Eur Urol 2007; Oct;52(4):948-50.. 119. Judge A, Evans S, Gunnell DJ, Albertsen PC, Verne J, Martin RM. Patient Outcomes and Length of Hospital Stay after Radical Prostatectomy for Prostate Cancer: analysis of Hospital Episodes Statistics for England. BJU Intl 2007. Nov;100(5):1040-9. 120. Seidenfeld J, Samson DJ, Albertsen PC. Competing Risks for Patients with Localized Prostate Cancer. JNCI 2007; 99(20):1498-1499. 121. Hussain S, Gunnell D, Donovan J, McPhail S, Hamdy F, Neal D, Albertsen P, Verne J, Stephens P, Trotter C, Martin RM. Secular Trends in Prostate Cancer Mortality, Incidence and Treatment: England and Wales 1975- 2004. BJU Inl 2008 Mar;101(5):547-555. PMCID: PMC2765909 122. Albertsen PC*. Predicting Survival for Men with Clinically Localized Prostate Cancer: what do we need in contemporary practice? Cancer 2008 Jan 1;112(1):1-3. 123. Bellera C, Hanley JA, Joseph L, Albertsen PC. Hierarchical Changepoint models for Biochemical Markers Illustrated by Tracking Post-Radiotherapy PSA Series in Men with Prostate Cancer. Ann Epidemiol 2008 Apr;18(4):270-82. 124. Bellera C, Hanley JA, Joseph L, Albertsen PC. Detecting Trends in Noisy Data Series: Application to Biomarker Series. Am J Epidemiol 2008 May 1;167(9):1130-9. 125. Albertsen P*. Should Men over the Age of 65 Years Receive PSA Screening? Argument Against. Nature Clinical Practice Urology 2008; 5(5):232-3. 126. Albertsen PC*. The Face of High Risk Prostate Cancer. World J Urol 2008 June; 26(3):205-10. 127. Dall’era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE Jr, Wallace ME, Kantoff PW, Carroll PR. Active Surveillance for Early-Stage Prostate Cancer: review of the current literature. Cancer 2008 Apr 15;112(8):1650-1659. 128. Albertsen P*. Should Patients Consider Active Surveillance? Cancer 2008 Jun 15;112(12):2631-2634. 129. Collin SM, Martin RM, Metcalfe C, Gunnell D, Albertsen PC, Neal D, Hamdy F, Stephens P, Lane JA, Moore R, Donovan J. Prostate-cancer Mortality in the USA and UK in 1975-2004: an ecological study. Lancet Oncol 2008 May;9(5):445-52. PMCID: PMC2760747 130. Albertsen P*. Should Men with Low-risk, Localized Prostate Cancer choose Active Surveillance or Undergo a Robotic Prostatectomy? Curr Urol Rep 2008 Jan;9(1):1-2.

131. Penson DF, McLerran D, Feng Z, Li L, Albertsen PC, Gilliland FD, Hamilton A, Hoffman RM, Stephenson RA, Potosky AL, Stanford JL. 5-Year Urinary and Sexual Outcomes after Radical Prostatectomy: results from the Prostate Cancer Outcomes Study. J Urol 2008 May;179(5 Suppl):S40-4. 132. Ercole B, Marietti SR, Fine J, Albertsen PC*. Outcomes Following Active Surveillance of Men with Localized Prostate Cancer Diagnosed in the PSA Era. J Urol 2008 Oct;180(4):1336-1339. 133. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL. Survival Following Primary Androgen Deprivation Therapy Among Men with Localized Prostate Cancer. JAMA 2008;300(2):173-181. PMCID: PMC2645653 134. Kakizoe T, Mucci LA, Albertsen PC, Droller MJ. Screening for Bladder Cancer: Theoretical and Practical Issues in Considering the Treated and Untreated Natural History of the Various Forms of the Disease. Scandinavian Jrl of Urol and Nephrology 2008; 42 (suppl 218):191-212. 135. Lu-Yao, GL, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery E, Barry MJ. Screening, Treatment and Prostate Cancer Mortality in the Seattle Area and Connecticut: Fifteen-year Follow-up. J Gen Int Med 2008 Nov;23(11):1809- 14. PMCID: PMC2585661 136. Albertsen PC*. The Treatment Paradigm Shifts Again on Prostate Cancer. Eur Urol 2009;55:9-11. 137. Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, Carter HB, Costantino JP, Epstein JI, Godley P, Harris RP, Wilt TJ, Wittes J, Zon R, Schellhammer P. Use of 5-alpha Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol 2009 Mar 20;27(9): 1502-1516. 138. Albertsen PC*. A Challenge to Contemporary Management of Prostate Cancer. Nat Clin Pract Urol 2009; Jan;6(1):12-13. 139. Albertsen PC*. Words of Wisdom. Eur Urol 2009 Apr;55(4):989-990. 140. Bellera C, Hanley JA, Joseph L, Albertsen PC. A Statistical Evaluation of Rules for Biochemical Failure following Radiotherapy in Men Treated for Prostate Cancer. Int J Radiat OncolBiol Phys 2009;75(5):1357-1363. 141. Kramer BS, Hagerty KL, Justman S, Somerfield MR, Albertsen PC, Blot WJ, Carter HB, Costantino JP, Epstein JI, Godley P, Harris RP, Wilt TJ, Wittes J, Zon R, Schellhammer P. Use of 5-alpha Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Urol 2009 Apr;181(4):1642-1657. 142. Donovan MJ, Khan FM, Fernandez G, Mesa-Tejada R, Sapir M, Zubek VB, Powell D, Fogarasi S, Vengrenyuk Y, Teverovskiy M, Segal MR, Karnes RJ, Gaffey TA, Busch C, Haggman M, Hlavcak P, Freedland SJ, Vollmer RT, Albertsen P, Costa J, Cordon-Cardo C. Personalized Prediction of Tumor Response and Cancer Progression on Prostate Needle Biopsy. J Urol 2009 Jul;182(1):125-132. 143. Roehrborn CG, Albertsen P, Stokes ME, Black L, Benedict A. First-year Costs of Treating Prostate Cancer: estimates from SEER-Medicare data. Prostate Cancer Prostatic Dis 2009;12(4), 355-60. 144. Albertsen P*. Androgen Deprivation in Prostate Cancer – Step by Step. N Engl J Med 2009 Jun 11;360(24)2572-4. 145. Albertsen PC*.The Unintended Burden of Increased Prostate Cancer Detection Associated with Prostate Cancer Screening and Diagnosis. Urology 2010 Feb;75(2):399-405. 146. Albertsen P*. Lies, Damn Lies, and Cancer Statistics. Eur Urol 56 (2009)592-593. 147. Welch HG, Albertsen PC. Prostate Cancer Diagnosis and Treatment after the Introduction of Prostate-Specific Antigen Screening: 1986-2005. JNCI 2009; Oct 7;101(19):1325-9. 148. Albertsen PC*. An Iatrogenic Confounding Variable. JNCI 2009 Oct. 21;101(20):1368-9 149. Delbanco T, Albertsen PC. A 72-Year Old Man with Localized Prostate Cancer – 14 Years Later. JAMA 2009 Sep 9;302(10):1105-6. 150. Albertsen PC*. Regionalizing Urologic Cancer Care: Appropriate Health Care Policy? Urologic Oncology: Seminars and Original Investigations 2010; (28):1-3. 151. Bailey DE, Wallace M, Latini DM, Hegarty J, Carroll PR, Klein EA, Albertsen PC. Measuring Illness Uncertainty in Men Undergoing Active Surveillance for Prostate Cancer. Jrl of App Nurs Res 24 (2011 Nov);193–199. 152. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O’Leary M, Walker- Corkery E, Yao S-L. Outcomes of Localized Prostate Cancer Following Conservative Management. JAMA 2009 Sep 16;302(11):1202-9. PMCID: PMC2822438 153. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban D, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate Specific Antigen Best Practice Statement: 2009 Update. J Urol 2009 Nov;182(5):2232-41. 154. Albertsen PC*. Does the Benefit Justify the Risk? JNCI 2010;102(1):1-2.

155. Shao YH, Albertsen PC, Roberts CB, Lin Y, Mehta AR, Stein MN, DiPaola RS, Lu-Yao GL. Risk Profiles and Treatment Patterns among Men Diagnosed as having Prostate Cancer and a Prostate Specific Antigen Level Below 4.0 ng/ml. Arch Intern Med 2010 Jul 26;170(14):1256-61. 156. Albertsen PC*. Efficacy versus Effectiveness in Prostate-Specific Antigen Screening. JNCI 2010;102(5):288-289. 157. Stokes ME, Black L, Benedict A, Roehrborn CG, Albertsen P. Long-Term Medical-Care Costs Related to Prostate Cancer: Estimates from Linked SEER-Medicare Data. Prostate Cancer Prostatic Dis 2010 Sept;13(3):278-284. 158. Hamilton AS, Albertsen PC, Johnson TK, Hoffman R, Morrell D, Deapen D, Penson DF. Trends in Treatment of Localized Prostate Cancer using Supplemented Cancer Registry Data. BJU Int 2011 Feb;107(4):576-584. 159. Albertsen PC*. Treatment of Localized Prostate Cancer: When is Active Surveillance Appropriate? Nat Rev Clin Oncol 2010 Jul;7(7):394-400. 160. Taxel P, Dowsett R, Richter L, Fall P, Klepinger A, Albertsen P. Risedronate Prevents Early Bone Loss and Increased Bone Turnover in the First 6 Months of Luteinizing Hormone-Releasing Hormone-Agonist Therapy for Prostate Cancer. BJU Intl 2010 Nov;106(10):1473-6. 161. Albertsen PC*. When is Active Surveillance the Appropriate Treatment for Prostate Cancer? Acta Oncologica 2011, 50 (Suppl 1):120-126. 162. Albertsen PC*. Further Support for Active Surveillance in the Management of Low-Volume, Low-Grade Prostate Cancer. Eur Uro. 2010 Dec;58(6):836-7. 163. Thong MSY, van de Poll-Franse L, Hoffman RM, Albertsen PC, Hamilton AS, Stanford JL, Penson DF. Diabetes Mellitus and Health-Related Quality of Life in Prostate Cancer: 5-Year Results from the Prostate Cancer Outcomes Study. BJU Int 2010 Nov 11:107(8):1223-1231. 164. Albertsen PC*. WHO International Consultation on Prostate Cancer: A Summary. Acta Oncol. 2011 Jun;50 Suppl 1:155-60 165. Gjertson CK, Albertsen PC. Use and Assessment of PSA in Prostate Cancer. Med Clin North Am 2011 Jan;95(1):191- 200. 166. Albertsen PC*. Active Surveillance Compared with Initial Treatment in Men with Low-Risk Prostate Cancer: a decision analysis. Eur Urol 2011 May;59(5);882-3. 167. Albertsen PC*, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of Comorbidity on Survival Among Men With Localized Prostate Cancer. J Clin Oncol. 2011 Apr 1;29(10):1335-41. 168. Roberts CB, Albertsen PC, Shao YH, Moore DF, Mehta AR, Stein MN, Lu-Yao GL. Patterns and Correlates of Prostate Cancer Treatment in Older Men. Am J Med 2011 Mar;124(3);235-243. 169. Albertsen PC*. The Timing and Extent of Androgen Ablative Therapy for Prostate Cancer: Weighing the Clinical Evidence. Endocrinol Metab Clin N Am 2011 In press. 170. Shao Y-H, Albertsen PC, Shih W, Roberts CB, Lu-Yao GL. The Impact of PSA Testing Frequency on Prostate Cancer Incidence and Treatment in Older Men. Prostate Cancer Prostatic Dis 2011 Dec;14(4):332-9. 171. Ginzburg S, Albertsen PC. The Timing and Extent of Androgen Deprivation Therapy for Prostate Cancer: Weighing the Clinical Evidence. Endocrinol Metab Clin North Am. 2011 Sep;40(3):615-23. 172. Catto JW, Robinson MC, Albertsen PC, Goepel JR, Abbod MF, Linkens DA, Davis M, Rosario DJ, Warren AY, Varma M, Griffiths DF, Grigor KM, Mayer NJ, Oxley JD, Deshmukh NS, Lane JA, Metcalfe C, Donovan JL, Neal DE, Hamdy FC. Suitability of PSA-detected Localised Prostate Cancers for Focal Therapy: Experience from the ProtecT Study. Br J Cancer 2011 Sept 27;105(7):931-7 173. Albertsen P. A Tale of 2 Perspectives: The Clinician and the Public Health Professional. Cancer 2011 Oct 17. 174. Bourke L, Chico TJA, Albertsen PC, Hamdy FC, Rosario DJ. Cardiovasccular Risk in Androgen Suppression: Underappreciated Under-researched and Unresolved. Heart 2011 Dec 7. 175. Makarov DV, Desai RA, Yu JB, Sharma R, Abraham N, Albertsen PC, Penson DF, Gross CP. The Population Level Prevalence and Correlates of Appropriate and Inappropriate Imaging to Stage Incident Prostate Cancer in the Medicare Population. J Urol 2012 Jan;187(1) ;97-102. 176. Bourke L. Chico TJ, Albertsen PC, Hamdy FC, Rosario DJ. Cardiovascular risk in androgen suppression: underappreciated, under-researched and unresolved. Heart. 2012 Mar, 98(5):345-8. PMID: 22155645. 177. Zhu X, Albertsen PC, Andriole GL, Roobol MJ, Schröder FH, Vickers AJ. Risk-Based Prostate Cancer Screening. Eur Urol. 2012 Apr: 61(4):652-61. 178. Makarov DV, Desai R, Yu JB, Sharma R, Abraham N, Albertsen PC, Krumholz HM, Penson DF, Gross CP. Appropriate and inappropriate imaging rates for prostate cancer go hand in hand by region, as if set by thermostat. Health Aff (Millwood). 2012 Apr;31(4):730-40 PMID: 22492890 179. Albertsen PC. How best to use our tools? Eur Urol. 2012 Aug;62(6):201-2. PMID: 22386191

180. Albertsen PC. Robot-assisted radical prostatectomy – fake innovation or the real deal? Eur Urol. 2012 Sep;62(3):365- 7. PMID:22705383 181. Lu-Yao GL, Albertsen PC, Li H, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL. Eur Urol. 2012 Dec;62(6):966-72. PMID: 22608160 182. Albertsen PC. What is the Risk Posed by Prostate Cancer? JNCI Monographs 2012 Dec:2012(45):169-174. 183. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P; erican Urological Association. J Urol. 2013 Jan; 189(1Suppl): S2-S11. PMID 23234625 184. Resnick MJ, Koyama T, Fan KH. Albertsen PC, Goodman M, Hamilton AS, Hoffman RM, Potosky AL, Stanford JL, Stroup AM, Van Horn RL, Penson DF. N Engl J Med. 2013 Jan 31; 368(5):436-45. PMID: 23363497 185. Struder UE. Albertsen PC. It’s time to change the treatment paradigm for prostate cancer! Eur Urol. 2013 Jan;63(1):97-9. Discussion 99-100. PMID: 22959353 186. Van den Bergh RC, Albertsen PC, Bangma CH, Freedland SJ, Graefen M, Vickers A, van der Poel HG. Timing of Curative Treatment for Prostate Cancer: A Systematic Review. Eur Urol. 2013 Feb 22. PMID:23453419 187. Noon AP, Albertsen PC, Thomas F, Rosario DJ, Catto JW. Competing mortality in patients diagnosed with bladder cancer: evidence of undertreatment in the elderly and female patients. BR J Cancer. 2013 Mar 12. PMID: 23481180

INVITED ARTICLES:

1. Albertsen PC*. Rising Health Care Costs: Who’s to Blame? Hartford Courant, September 23, 1990. 2. Albertsen PC*. The Medicare Pie: How will it be Sliced? AUA Today, October 1990. 3. Albertsen PC*. Health Care in America: Where are We Going? AUA Today, March 1991. 4. Albertsen PC*. Prospective Payment System: Rent Control for Health Care? AUA Today, October 1991. 5. Albertsen PC*. Fracchia J. Alternative to Recertification Needed. AUA Today, April 1992. 6. Albertsen PC*. Urologist Expresses Views on Recertification. Clinical Urology Forum 1992, 4:5. 7. Albertsen PC*. Decision Making in Urology. 1995 Monographs in Urology 1995, 16:69-82. 8. Naitoh J, Albertsen PC.* Current Concepts in Prostate Cancer Screening. Cortlandt Forum, June, 1996. 9. Albertsen PC*, Baum N. Nine Strategies for Making Your Urology Practice Managed Care-Friendly. Cont Urol. 8(12):13-27, 1996. 10. Onel E, Albertsen PC*. Management of Impotence. Cortlandt Forum 1997, 10:271-274. 11. Murphy-Setzko M., Albertsen PC*. Persistently Recurring Urinary Tract Infection. Cortlandt Forum January, 1997. 12. Kolon TF, Albertsen PC*. Diagnosis and Treatment of Scrotal Abnormalities. Cortlandt Forum 1997; 10:210-221. 13. Albertsen PC*. The Dilemma over PSA Screening. Cortlandt Forum 2001, 14:80. 14. Albertsen PC*. The Role of PSA Screening in Early Detection of Prostate Cancer. Principles and Practice of Oncology, Updates, 2001;15:1-16.

BOOK CHAPTERS

1. Albertsen PC*, Wasson JH, Barry MJ. Observation as a Treatment Option Among Men with Clinically Localized Prostate Cancer. Current Clinical Oncology 1994, 12:185-196. 2. Albertsen PC*. Early Stage Prostate Cancer: When is Observation Appropriate? Hematology/Oncology Clinics of North America 1996, 10:611-625. 3. Albertsen PC*. Screening for Prostate Cancer is Neither Appropriate Nor Cost Effective. Urologic Clinics of North America. 1996, 23:1-9. 4. Albertsen PC*. Decreasing Prostate Cancer Mortality in the USA. Is the Value of Screening Already Proven? Renal, Bladder and Prostate Cancer: An Update. Schröder FH Editor. The Parthanon Publishing Group: , 1999. 5. Albertsen PC*. A Current Synthosis of the Management of Prostate Cancer. When is observation appropriate? Current Clinical Urology: Management of Prostate Cancer. E.A. Klein, Ed. Totowa, NJ: Humana Press, Inc. 1999, pp. 103-116. 6. Albertsen PC*. Chapter 3: Prostate Cancer. Classic Papers in Urology. Oxford England: Isis Medical Media LTD, 1999, pp.45-65. 7. Albertsen PC*. Chapter 1: Epidemiology of Prostate Cancer: An Overview. Advanced Therapy in Prostate Disease. Resnick M and Thompson IA, Editors. Hamilton, Ontario: BC Decker, Inc. 2000, pp. 1-5 8. Albertsen PC*. Chapter 42A: Treatment of Early Stage Prostate Cancer - Expectant Management. Comprehensive Textbook of Genitourinary Oncology. Vogelzang N, Editors. Philadelphia, Lippincott, Williams & Wilkens, 2000.

9. Albertsen PC*. Chapter 61: Benign and Malignant Diseases of the Prostate. Principles and Practices in Geriatric Surgery. Rosenthal RA, Zenilman M, and Katlic M, Editors. Springer-Verlag, 2000, pp 806-816. 10. Albertsen PC* Chapter 2: Natural History of Prostate Cancer. Current Clinical Concepts: Prostate Cancer Screening. Thompson IM, Resnick MI, Klein EA, Editors, Humana Press 2001. 11. Albertsen PC*. Chapter 13: Clinical Epidemiology: Incidence Rates, Databases, Age, and Co-Morbidity. Prostate Cancer Principles & Practice. Kantoff PW, Carroll PR, D’Amico AV, Editors. Ross RK, Isaacs JT, Scher HI, section editors. Lippincott, Williams & Wilkins, Philadelphia 2002, pp. 178-192. 12. Schroeder FH, Albertsen PC, Boyle P, Candas B, Catalona W, Cheng C, DeKonig HJ, Fourcade R, Hugosson J, Moul J, Perrin P, Roehrborn C, Rubben H, Stephenson R, Yamanaka H. Early detection and screening for prostate cancer. Prostate Cancer. Denis L, Bartsch G, Khoury S, Murai M, Partin A editors. Paris: Health Publication – 2003, 2003. 13. Fine J, Albertsen PC*. Chapter 3: Budget Development and Staffing. Clinical Research Methods for Surgeons. Wei JT, Penson DF editors. Humana Press 2006, pp. 47-60. 14. Marietti SR, Albertsen PC. Prostate Cancer Screening. Therapeutic Strategies in Prostate Cancer. Fenely and Payne 2007. 15. Albertsen, PC*. Chapter 1: Mortality Trends in Prostate Cancer. Treatment Methods for Early and Advanced Prostate Cancer. Kirby, RS, Partin AW, Parsons JK, Feneley MR Editors. Informa UK Ltd 2008, pp. 3-8. 16. Albertsen, PC*. Chapter 61: Screening for Prostate Cancer. CANCER: Principles & Practice of Oncology, 9th ed. DeVita V, DePinho RA, Lawrence TS, Rosenberg SA, Weinberg RA editors. Lippincott Williams &Wilkins, Philadelphia. May 2011.

BOOK REVIEWS

1. Albertsen PC*. “Preventing Prostate cancer: Screening versus Chemoprevention.”.JNCI 1995, 87:1714. 2. Albertsen PC*. “How I Survived Prostate Cancer... and so can You”. JNCI 1995, 87:1085. 3. Albertsen PC*. “Controversies in the Treatment of Prostate Cancer”, N Engl J Med 360(3):311-312, January 15, 2009.

LETTERS TO THE EDITOR

1. Albertsen PC*. A 72 year-old man with localized prostate cancer. JAMA 1995, 247:1426-27. 2. Albertsen PC*. Survival and conservative treatment for localized prostate cancer. JAMA 1996, 275:31. 3. Fryback DG, Albertsen PC, Storer BE. Prostatectomy and survival among men with clinically localized prostate cancer. JAMA 1996, 276:1723-24. 4. Albertsen PC*, Fryback DG, Storer BE, Kolon TF, Fine J. The impact of co-morbidity on life expectancy among men with localized prostate cancer J Urol 1997, 157:694-5. 5. Albertsen PC*, Quality of Life and Advanced Cancer”. JNCI 1999, 91:646. 6. Bellera CA, Hanley JA, Joseph L, Albertsen PC. A Charting Tool for Estimating the PSA Doubling Time in Patients with Prostate Cancer. International Journal of Radiation Oncology*Biology*Physics 2006, 66(1). 7. Albertsen PC*. Reply to: PSA Screening and Elderly Men. JAMA 2007, 297(9):949-950 8. Lu-Yao G, Barry M, Albertsen PC, Yao SL . Outcomes of Treatment vs. Observation of Localized Prostate Cancer in Elderly Men. JAMA 2007, 297(15):1651. 9. Editorial Comment. Albertsen PC. Urology. 2012 Oct;80(4):888. PMID 22921701 10. Albertsen PC. Critical role of prostate biopsy mortality in the number of years of life gained and lost within a prostate cancer screening programme. BJU Int. 2012 Dec;110(11):1653. PMID: 2298489

*corresponding author